Key clinical point : Adding immunotherapy to chemotherapy for early triple-negative breast cancer did not increase symptom burden.
Major finding : Health-related quality-of-life measures were similar whether patients received chemotherapy with atezolizumab or with placebo. For example, mean physical function scores were about 90% in both treatment arms at baseline, dropped to about 65% in each arm by cycle 5, and rebounded to about 80% by cycle 7.
Study details : Exploratory patient-reported outcomes from 328 patients in the phase 3 IMpassion031 trial.
Disclosures: IMpassion031 is sponsored by F. Hoffman-LaRoche. Dr. Mittendorf disclosed relationships with Roche/Genentech, GlaxoSmithKline, Physicians’ Education Resource, AstraZeneca, Exact Sciences, Merck, Peregrine Pharmaceuticals, SELLAS Life Sciences, TapImmune, EMD Serono, Galena Biopharma, Bristol Myers Squibb, and Lilly.
Source: Mittendorf E at al. SABCS 2020, Abstract GS3-02 .